These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9468359)

  • 1. Altered consciousness states and endogenous psychoses: a common molecular pathway?
    Ciprian-Ollivier J; Cetkovich-Bakmas MG
    Schizophr Res; 1997 Dec; 28(2-3):257-65. PubMed ID: 9468359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ayahoasca: an experimental psychosis that mirrors the transmethylation hypothesis of schizophrenia.
    Pomilio AB; Vitale AA; Ciprian-Ollivier J; Cetkovich-Bakmas M; Gómez R; Vázquez G
    J Ethnopharmacol; 1999 Apr; 65(1):29-51. PubMed ID: 10350367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.
    Gouzoulis-Mayfrank E; Heekeren K; Neukirch A; Stoll M; Stock C; Obradovic M; Kovar KA
    Pharmacopsychiatry; 2005 Nov; 38(6):301-11. PubMed ID: 16342002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypotheses regarding the mechanisms of ayahuasca in the treatment of addictions.
    Liester MB; Prickett JI
    J Psychoactive Drugs; 2012; 44(3):200-8. PubMed ID: 23061319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the comparative ethnopharmacology of malpighiaceous and myristicaceous hallucinogens.
    McKenna DJ; Towers GH
    J Psychoactive Drugs; 1985; 17(1):35-9. PubMed ID: 3856652
    [No Abstract]   [Full Text] [Related]  

  • 6. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca.
    McKenna DJ; Towers GH; Abbott F
    J Ethnopharmacol; 1984 Apr; 10(2):195-223. PubMed ID: 6587171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A longitudinal study of urinary excretion of N,N,-dimethyltryptamine in psychotic patients.
    Checkley SA; Murray RM; Oon MC; Rodnight R; Birley JL
    Br J Psychiatry; 1980 Sep; 137():236-9. PubMed ID: 6777009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonergic Hallucinogen-Induced Visual Perceptual Alterations.
    Kometer M; Vollenweider FX
    Curr Top Behav Neurosci; 2018; 36():257-282. PubMed ID: 27900674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity.
    Frecska E; Szabo A; Winkelman MJ; Luna LE; McKenna DJ
    J Neural Transm (Vienna); 2013 Sep; 120(9):1295-303. PubMed ID: 23619992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale.
    Strassman RJ; Qualls CR; Uhlenhuth EH; Kellner R
    Arch Gen Psychiatry; 1994 Feb; 51(2):98-108. PubMed ID: 8297217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous hallucinogens as ligands of the trace amine receptors: a possible role in sensory perception.
    Wallach JV
    Med Hypotheses; 2009 Jan; 72(1):91-4. PubMed ID: 18805646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A test of the transmethylation hypothesis in acute schizophrenic patients.
    Carpenter WT; Fink EB; Narasimhachari N; Himwich HE
    Am J Psychiatry; 1975 Oct; 132(10):1067-71. PubMed ID: 1058643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine.
    Jacob MS; Presti DE
    Med Hypotheses; 2005; 64(5):930-7. PubMed ID: 15780487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors.
    Smith RL; Canton H; Barrett RJ; Sanders-Bush E
    Pharmacol Biochem Behav; 1998 Nov; 61(3):323-30. PubMed ID: 9768567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DMT at fifty.
    Szára S
    Neuropsychopharmacol Hung; 2007 Dec; 9(4):201-5. PubMed ID: 18510265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary dimethyltryptamine and psychiatric symptomatology and classification.
    Rodnight R; Murray RM; Oon MC; Brockington IF; Nicholls P; Birley JL
    Psychol Med; 1976 Nov; 6(4):649-57. PubMed ID: 1070024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges.
    McKenna DJ
    Pharmacol Ther; 2004 May; 102(2):111-29. PubMed ID: 15163593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of recent studies of the biosynthesis and excretion of hallucinogens formed by methylation of neurotransmitters or related substances.
    Rosengarten H; Friedhoff AJ
    Schizophr Bull; 1976; 2(1):90-105. PubMed ID: 779022
    [No Abstract]   [Full Text] [Related]  

  • 19. The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs.
    Riga MS; Soria G; Tudela R; Artigas F; Celada P
    Int J Neuropsychopharmacol; 2014 Aug; 17(8):1269-82. PubMed ID: 24650558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans.
    Strassman RJ; Qualls CR; Berg LM
    Biol Psychiatry; 1996 May; 39(9):784-95. PubMed ID: 8731519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.